• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

两种三唑类抗真菌剂（伏立康唑[UK-109,496]和氟康唑）对念珠菌属的体外研究。

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.

作者信息

Barry A L, Brown S D

机构信息

Clinical Microbiology Institute, Tualatin, Oregon 97062, USA.

出版信息

Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.

DOI:10.1128/AAC.40.8.1948
PMID:8843312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163448/
Abstract

A new triazole derivative (voriconazole or UK-109,496) and fluconazole were tested against 249 isolates of Candida spp. representing six species. Voriconazole was 10 to 100 times more potent than fluconazole. Strains with decreased susceptibility to fluconazole were inhibited by relatively low concentrations of voriconazole.

摘要

一种新的三唑衍生物（伏立康唑或UK-109,496）和氟康唑针对代表6个种的249株念珠菌属分离株进行了测试。伏立康唑的效力比氟康唑强10至100倍。对氟康唑敏感性降低的菌株被相对低浓度的伏立康唑所抑制。

相似文献

1
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.两种三唑类抗真菌剂（伏立康唑[UK-109,496]和氟康唑）对念珠菌属的体外研究。
Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.
2
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.一种新型三唑类药物伏立康唑（UK-109,496）可阻断白色念珠菌和克鲁斯念珠菌中的甾醇生物合成。
Antimicrob Agents Chemother. 1997 Nov;41(11):2492-6. doi: 10.1128/AAC.41.11.2492.
3
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.伏立康唑和伊曲康唑对来自西班牙的念珠菌属氟康唑敏感及氟康唑耐药临床分离株的体外活性比较
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.
4
The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells.新型三唑类药物伏立康唑（UK-109,496）对白色念珠菌和克鲁斯念珠菌与内皮细胞相互作用的影响。
J Chemother. 1998 Feb;10(1):7-16. doi: 10.1179/joc.1998.10.1.7.
5
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.伏立康唑（UK-109,496）及其他四种抗真菌药物对394株念珠菌属临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Jan;42(1):161-3. doi: 10.1128/AAC.42.1.161.
6
Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.在13338株念珠菌属临床分离株中，使用氟康唑作为替代标志物来预测对伏立康唑的敏感性和耐药性。采用临床和实验室标准协会推荐的肉汤微量稀释法进行检测。
J Clin Microbiol. 2007 Jan;45(1):70-5. doi: 10.1128/JCM.01551-06. Epub 2006 Nov 1.
7
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].氟康唑、伏立康唑和泊沙康唑对念珠菌属的体外活性
Rev Esp Quimioter. 2003 Jun;16(2):227-32.
8
In vitro activity of voriconazole against Candida species.伏立康唑对念珠菌属的体外活性。
Diagn Microbiol Infect Dis. 1998 May;31(1):297-300. doi: 10.1016/s0732-8893(98)00005-4.
9
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.伏立康唑（UK-109,496）对来自人类免疫缺陷病毒感染患者口腔的氟康唑敏感及耐药白色念珠菌分离株的体外活性。
Antimicrob Agents Chemother. 1997 Mar;41(3):575-7. doi: 10.1128/AAC.41.3.575.
10
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.伏立康唑对氟康唑敏感和耐药念珠菌分离株的作用：与伊曲康唑和酮康唑相比的体外疗效
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.

引用本文的文献

1
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.DectiSomes：靶向 C 型凝集素受体的脂质体作为泛抗真菌药物。
Adv Drug Deliv Rev. 2023 May;196:114776. doi: 10.1016/j.addr.2023.114776. Epub 2023 Mar 17.
2
A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.近二十年获批上市的抗生素概述：回顾与展望。
Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.
3
Voriconazole-induced periostitis: a new rheumatic disorder.伏立康唑诱发的骨膜炎：一种新的风湿性疾病。
Clin Rheumatol. 2017 Mar;36(3):609-615. doi: 10.1007/s10067-016-3341-7. Epub 2016 Jul 4.
4
Invasive fungal infections in the ICU: how to approach, how to treat.重症监护病房中的侵袭性真菌感染：如何诊治。
Molecules. 2014 Jan 17;19(1):1085-119. doi: 10.3390/molecules19011085.
5
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.采用新型高效液相色谱法和生物测定法测定伏立康唑血药浓度的变异性。
Antimicrob Agents Chemother. 2007 Jan;51(1):137-43. doi: 10.1128/AAC.00957-06. Epub 2006 Nov 6.
6
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.针对念珠菌属对伏立康唑的药敏试验，最小抑菌浓度（MIC）与结果的相关性分析及解释性折点建议
J Clin Microbiol. 2006 Mar;44(3):819-26. doi: 10.1128/JCM.44.3.819-826.2006.
7
Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.Etest法与改良肉汤微量稀释法检测曲霉属对伏立康唑敏感性的比较。
J Clin Microbiol. 2003 Nov;41(11):5270-2. doi: 10.1128/JCM.41.11.5270-5272.2003.
8
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.伏立康唑、泊沙康唑及四种已获许可的全身用抗真菌药对从血液中罕见分离出的念珠菌属的体外活性。
J Clin Microbiol. 2003 Jan;41(1):78-83. doi: 10.1128/JCM.41.1.78-83.2003.
9
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.伏立康唑对一名肝移植受者及人肝微粒体中他克莫司代谢的抑制作用。
Antimicrob Agents Chemother. 2002 Sep;46(9):3091-3. doi: 10.1128/AAC.46.9.3091-3093.2002.
10
Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.卡泊芬净单独及与伏立康唑联合在豚鼠侵袭性曲霉病模型中的疗效。
Antimicrob Agents Chemother. 2002 Aug;46(8):2564-8. doi: 10.1128/AAC.46.8.2564-2568.2002.